Polysaccharide from Panax japonicus CA Mey prevents non-alcoholic fatty liver disease development based on regulating liver metabolism and gut microbiota in mice

被引:10
|
作者
Wu, Yi [1 ]
Yin, Wen [1 ]
Hao, Ping [1 ]
Chen, Yueru [1 ,3 ]
Yu, Lingyun [1 ]
Yu, Xingjian [4 ]
Wu, Yu [1 ,5 ]
Li, Xiaocong [6 ]
Wang, Wenjia [1 ,7 ]
Zhou, Hui [1 ]
Yuan, Yuan [1 ]
Quan, Xiaoyu [1 ]
Yu, Yue [1 ]
Hu, Bing [1 ]
Chen, Shouhai [1 ]
Zhou, Zhenlei [1 ]
Sun, Wenjing [2 ]
机构
[1] Nanjing Agr Univ, Coll Vet Med, Nanjing 210095, Peoples R China
[2] Yulin Normal Univ, Coll Biol & Pharm, Guangxi Key Lab Agr Resources Chem & Biotechnol, 1303 Jiaoyu East Rd, Yulin 537000, Peoples R China
[3] Shandong Univ Tradit Chinese Med, Coll Pharm, Jinan 250355, Peoples R China
[4] Univ Calif Davis, Dept Biochem & Mol Med, Sch Med, Sacramento, CA 95817 USA
[5] Nanjing Med Univ, Ctr Global Hlth, Dept Pathogen Biol & Immunol, Jiangsu Key Lab Pathogen Biol, Nanjing 211166, Jiangsu, Peoples R China
[6] Hubei Three Gorges Polytech, 31 Stadium Rd, Yichang 443000, Peoples R China
[7] Ningxia Univ, Coll Anim Sci & Technol, Yinchuan, Peoples R China
基金
中国国家自然科学基金;
关键词
China; Panax japonicus polysaccharides; Non-alcoholic fatty liver disease; Gut microbiota; Metabolism; NAFLD;
D O I
10.1016/j.ijbiomac.2024.129430
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this study, a new polysaccharide (PSPJ) with specific molecular weight and monosaccharide compositions was isolated and purified from the water extract of Panacis Japonici Rhizoma (PJR). 16S rRNA analysis and untargeted metabolomic analysis were used to assess PSPJ's efficacy in averting non-alcoholic fatty liver disease (NAFLD). This study indicated that PSPJ significantly reduced liver fat accumulation, the increase in blood lipids and ALT caused by HFD, indicating that PSPJ can prevent NAFLD. We demonstrated through cell experiments that PSPJ does not directly affect liver cells. The gut microbiota disorder and alterations in short-chain fatty acids (SCFAs) induced by the high-fat diet (HFD) were ameliorated by PSPJ, as evidenced by the analysis of 16S rRNA. In particular, supplementing PSPJ reduced the abundance of Turicibacter, Dubosiella, and Staphylococcus, and increased the abundance of Bacteroides, Blautia, and Lactobacillus. Untargeted metabolomic analysis shows that PSPJ improves liver metabolic disorders by regulating arachidonic acid metabolism, carbohydrate digestion and absorption, fatty acid biosynthesis, fatty acid metabolism and retinol metabolism. The findings of our investigation indicate that PSPJ has the potential to modulate liver metabolism through alterations in the composition of intestinal bacteria, hence preventing NAFLD.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?
    Demir, Muenevver
    Lang, Sonja
    Martin, Anna
    Farowski, Fedja
    Wisplinghoff, Hilmar
    Vehreschild, Maria J. G. T.
    Krawczyk, Marcin
    Nowag, Angela
    Scholz, Claus Jurgen
    Kretzschmar, Anne
    Roderburg, Christoph
    Lammert, Frank
    Goeser, Tobias
    Kasper, Philipp
    Steffen, Hans-Michael
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (11) : 1969 - 1977
  • [42] Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie, Chencheng
    Halegoua-DeMarzio, Dina
    NUTRIENTS, 2019, 11 (11)
  • [43] Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota
    Ruiting Han
    Junli Ma
    Houkai Li
    Frontiers of Medicine, 2018, 12 : 645 - 657
  • [44] Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Non-alcoholic Fatty Liver Disease
    Ralli, Tanya
    Neupane, Yub Raj
    Saifi, Zoya
    Kohli, Kanchan
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (46) : 4677 - 4685
  • [45] Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota
    Doulberis, Michael
    Kotronis, Georgios
    Gialamprinou, Dimitra
    Kountouras, Jannis
    Katsinelos, Panagiotis
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 71 : 182 - 197
  • [46] Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD)
    Burz, Sebastian D.
    Monnoye, Magali
    Philippe, Catherine
    Farin, William
    Ratziu, Vlad
    Strozzi, Francesco
    Paillarse, Jean-Michel
    Chene, Laurent
    Blottiere, Herve M.
    Gerard, Philippe
    MICROORGANISMS, 2021, 9 (01) : 1 - 27
  • [47] Shenling Baizhu San ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites
    Chen, Dongliang
    Wang, Yuanfei
    Yang, Jianmei
    Ou, Wanyi
    Lin, Guiru
    Zeng, Ze
    Lu, Xiaomin
    Chen, Zumin
    Zou, Lili
    Tian, Yaling
    Wu, Aiping
    Keating, Shelley E.
    Yang, Qinhe
    Lin, Chenli
    Liang, Yinji
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [48] Camphor Seed Kernel Oil Beneficial Effects the Gut Microbiota of the Non-Alcoholic Fatty Liver Disease Mice
    Wang, Baogui
    Wang, Jun
    Du, Wen
    Shang, Shuai
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2022, 27 (07):
  • [49] Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease
    Ali Abdul-Hai
    Ali Abdallah
    Stephen DH Malnick
    World Journal of Hepatology, 2015, (12) : 1679 - 1684
  • [50] Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease
    Abdul-Hai, Ali
    Abdallah, Ali
    Malnick, Stephen D. H.
    WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (12) : 1679 - 1684